Postherpetic neuralgia (PHN)
Conditions
Interventions
Experimental group:Esketamine: According to previous studies and FDA's recommended dosing schedule, the investigator administered the drug at 0.15mg/kg/h, diluted to 100ml with normal saline, placed i
Control group:Saline IV
Sponsors
Taiyuan Central Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 and =4. 3.Informed consent was obtained;
Exclusion criteria
Exclusion criteria: 1.Previous allergy to ketamine or esketamine; 2.Pregnant, breastfeeding, or recently preparing for pregnancy; 3.Patients with poorly controlled hypertension (systolic blood pressure >160mmHg or diastolic blood pressure >90mmHg), severe sinus tachycardia (heart rate >100 beats per minute) or tachyarrhythmia, New York Heart Association (NYHA) class ? or higher, or untreated coronary artery disease; 4.Transient ischemic attack, stroke, cerebral hemorrhage, craniocerebral injury or neurosurgical operation, low intracranial pressure or high intracranial pressure disease should not exceed 3 months; 5.Poorly controlled mental illness; 6.history of aneurysms such as thoracic aortic aneurysm, abdominal aortic aneurysm, intracranial aneurysm, or peripheral arterial disease or arteriovenous malformations; 7.Alcohol abuse, drug abuse/dependence (within 6 months); 8.Severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (on dialysis); 9.A history of uncontrolled hyperthyroidism; 10.History of glaucoma; 11.The following contraindications were used:Aminophylline, theophylline,Cyclosporine, fluconazole, ketoconazole, erythromycin, itraconazole, cimetidine, tamoxifen, verapamil, and amiodaron,Phenobarbital, rifampicin, carbamazepine, phenytoin, reserpine, macrolides, and glucocorticoidsErgonovine, thyroid hormone, vasopressin, sympathomimetic drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS score at 48h posttreatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug adverse effect score posttreatment;Adverse Event Rate during follow-up;ID-pain score;SF-MPG-2;STAI score;FOP score;PCS score;PSQI;SF-36 score;Numeric rating scales; | — |
Countries
China
Contacts
Public ContactZengmao Lin
Peking University First Hospital
Outcome results
None listed